Skip to main content

Longitudinal change in ATN biomarkers in cognitively normal individuals



Biomarkers for amyloid, tau, and neurodegeneration (ATN) have predictive value for clinical progression, but it is not clear how individuals move through these stages. We examined changes in ATN profiles over time, and investigated determinants of change in A status, in a sample of cognitively normal individuals presenting with subjective cognitive decline (SCD).


We included 92 individuals with SCD from the SCIENCe project with [18F]florbetapir PET (A) available at two time points (65 ± 8y, 42% female, MMSE 29 ± 1, follow-up 2.5 ± 0.7y). We additionally used [18F]flortaucipir PET for T and medial temporal atrophy score on MRI for N. Thirty-nine individuals had complete biomarker data at baseline and follow-up, enabling the construction of ATN profiles at two time points. All underwent extensive neuropsychological assessments (follow-up time 4.9 ± 2.8y, median number of visits n = 4). We investigated changes in biomarker status and ATN profiles over time. We assessed which factors predisposed for a change from A− to A+ using logistic regression. We additionally used linear mixed models to assess change from A− to A+, compared to the group that remained A− at follow-up, as predictor for cognitive decline.


At baseline, 62% had normal AD biomarkers (A−T−N− n = 24), 5% had non-AD pathologic change (A−T−N+ n = 2,) and 33% fell within the Alzheimer’s continuum (A+T−N− n = 9, A+T+N− n = 3, A+T+N+ n = 1). Seventeen subjects (44%) changed to another ATN profile over time. Only 6/17 followed the Alzheimer’s disease sequence of A → T → N, while 11/17 followed a different order (e.g., reverted back to negative biomarker status). APOE ε4 carriership inferred an increased risk of changing from A− to A+ (OR 5.2 (95% CI 1.2–22.8)). Individuals who changed from A− to A+, showed subtly steeper decline on Stroop I (β − 0.03 (SE 0.01)) and Stroop III (− 0.03 (0.01)), compared to individuals who remained A−.


We observed considerable variability in the order of ATN biomarkers becoming abnormal. Individuals who became A+ at follow-up showed subtle decline on tests for attention and executive functioning, confirming clinical relevance of amyloid positivity.


The most common cause of dementia is Alzheimer’s disease (AD), which is characterized by the accumulation of amyloid beta plaques and neurofibrillary tau tangles [1]. The ATN classification provides a framework to diagnose AD based on biomarkers providing an indication of these pathologic changes [2]. In this framework, individuals are classified by the presence or absence of amyloid (A), hyperphosphorylated tau (T), and neurodegeneration (N), resulting in eight possible ATN profiles. We previously showed that in cognitively normal individuals with subjective cognitive decline (SCD), A+ was associated with a higher risk of dementia [3].

According to the amyloid cascade hypothesis, the accumulation of amyloid in the brain initiates a series of events including the formation of neurofibrillary tau tangles and neuronal cell loss, eventually resulting in cognitive decline [4]. Therefore, it is assumed that individuals become A+ before turning T+ or N+. Only a few studies evaluated the temporal ordering of ATN biomarker abnormality in a longitudinal manner. One study in a mixed population of cognitively normal individuals and individuals with mild cognitive impairment (MCI) indeed found that most often, A became abnormal first, yet also described there were multiple routes, specifically A → T → N, A → N → T, T → A → N and N → A → T [5].

In the ATN classification, biomarkers are treated as dichotomous variables. With research interest shifting to the very early stages of AD, “grey zone” amyloid burden and subthreshold amyloid accumulation were found to be associated with memory decline, showing additional value of amyloid burden in the perithreshold range [6,7,8]. One study in a population consisting of cognitively normal and MCI individuals investigated change from A− to A+ rather than accumulation rate and found that lower baseline cognition and APOE ε4 carriership were predictive of changing to A+ [9]. Investigating determinants of amyloid accumulation, specifically in the early stages of disease, therefore has clinical relevance.

The aims of this study were to (1) identify determinants of change in amyloid status, (2) describe changes in ATN profiles over time, and (3) evaluate change in amyloid status as predictor of cognitive decline, in cognitively normal individuals.



We included cognitively normal participants with subjective cognitive decline (SCD) from the Subjective Cognitive Impairment Cohort (SCIENCe) at the Alzheimer Center Amsterdam who had two [18F]florbetapir PET scans available (n = 92). Individuals were referred to the memory clinic (n = 85) by their general physician, a neurologist, or a geriatrician and underwent an extensive standardized diagnostic workup that included a neurologic and neuropsychological examination, laboratory testing, and brain MRI. In a consensus meeting, participants were labeled SCD when cognitive performance appeared within normal limits, and criteria were not met for mild cognitive impairment (MCI), dementia, or other neurological or psychiatric diseases that could possibly cause cognitive complaints. Individuals received a diagnosis of MCI when they had cognitive impairment in one or more cognitive domains, while independence in functional abilities was still preserved [10]. Individuals were diagnosed with dementia when they had cognitive impairment in two or more cognitive domains, which interfered with daily activities [1].

In addition, seven participants were included via the Dutch Brain Research Registry ( They experienced cognitive complaints in absence of objective impairment and received the same baseline work-up. At annual follow-up visits, neuropsychological testing was repeated and diagnoses were re-evaluated.

PET and MRI acquisition

Baseline dynamic [18F]florbetapir PET scans were acquired on a Philips Ingenuity TF PET-CT (n = 82) or a Philips Gemini TF PET-CT (n = 10; Philips, Best, the Netherlands) scanner. These scanners were calibrated to each other. The scan protocol started with a low-dose CT for attenuation correction. Dynamic PET scans of 90 min (n = 82) were obtained starting directly after tracer injection of approximately 370 MBq [18F]florbetapir. During the course of the study, we demonstrated that scan duration could be reduced without compromising the reliability of results [11]. Therefore, subsequent scans had a duration of 70 minutes (n = 9). One scan was terminated early after 79 min due to participant related issues. All underwent a follow-up [18F]florbetapir PET with a mean follow-up time of 2.5 ± 0.7 years (n = 17 90-min scan; n = 75 a 70-min scan). All scans were visually assessed as “positive” or “negative” by a trained nuclear physician, blinded to the amyloid status at the other time point.

Baseline dynamic [18F]flortaucipir PET scans were acquired on a Philips Ingenuity TF PET-CT scanner (Philips, Best, the Netherlands, n = 44). Because substantial tau pathology within A− cognitively normal individuals is not expected to be present, we selected more A+ individuals for the [18F]flortaucipir PET in order to have a broader spectrum of amyloid and tau pathology, resulting in an A+ rate of this subset of about 33%. The scan protocol started with a low-dose CT for attenuation correction. Starting simultaneously with tracer injection of approximately 240 MBq [18F]flortaucipir, a 60-min dynamic emission scan was initiated. After a 20-min break and following a second low-dose CT for attenuation correction, an additional dynamic emission scan was performed during the interval 80–130 min post-injection. This dual time point protocol was validated previously [12]. Forty-two individuals underwent a follow-up [18F]flortaucipir PET scan using the same procedure with a mean follow-up time of 2.1 ± 0.3 years.

Baseline structural MRI images were obtained at five different systems (GE Discovery MR750 3T (n = 22), Philips PETMR 3T (n = 51), Signa 1.5T (n = 1), Titan 3T (n = 17), and external scan (n = 1)). The protocol included 3D T1-weighted images, 3D T2-weighted images, and 3D T2-weighted fluid-attenuated inversion-recovery (FLAIR) images [13]. T1-weighted images were used for coregistration to PET images and for determination of the N status. Follow-up MRI was available for 79 individuals with a mean follow-up time of 2.9 ± 0.9 years.

Image analysis

Data were reconstructed while using standard LOR RAMLA reconstruction algorithm with corrections for dead time, decay, attenuation, random coincidences, and scatter. Images were reconstructed with a matrix size of 128 × 128 × 90 and a voxel size of 2 × 2 × 2 mm3. For [18F]flortaucipir, both scan sessions (0–60 and 80–130 min) were co-registered into a single dataset of 29 frames (1 × 15, 3 × 5, 3 × 10, 4 × 60, 2 × 150, 2 × 300, 4 × 600, and 10 × 300 s), in which the last 10 frames belonged to the second PET session. 3D T1-weighted MR images were co-registered to PET images using Vinci software (Max Planck Institute, Cologne, Germany). Next, regions of interest (ROIs) were defined on the co-registered MRI using the probabilistic Hammers brain atlas [14] in PVElab. Receptor parametric mapping (RPM) was used to generate parametric binding potential (BPND) images with cerebellar grey matter as a reference region using PPET [11, 15,16,17]. For [18F]florbetapir, we calculated (volume weighted) mean cortical BPND in a composite ROI consisting of orbitofrontal, temporal, parietal, anterior cingulate, posterior cingulate, and precuneus regions [6, 18].

Biomarkers: a, T, N

Availability of biomarker status at two time points differed for each of the biomarkers (A: n = 92; T: n = 42; N: n = 79). For 39 individuals, a complete ATN profile over time could be constructed. The time difference with the [18F]florbetapir scan was 0.05 ± 0.15y for [18F]flortaucipir scans and 0.16 ± 0.62y for MRI scans. We used visual assessment of [18F]florbetapir PET scans to define A in the ATN classification. Since quantitative threshold-based methods usually have a high degree of concordance with visual assessment [19, 20], we chose visual assessment to be consistent with methods used in clinical practice. In additional analyses, we used continuous mean cortical BPND in a composite ROI. We used [18F]flortaucipir PET scans as biomarker for T. We pragmatically used Gaussian mixture modeling as an unbiased, data-driven approach, to obtain a threshold. We first averaged values for the anterior part of the lateral temporal lobe for left and right sides. Since the focus of this study was on cognitively unimpaired individuals, we a priori decided to select this region of interest to capture the earliest changes in neocortical areas [21]. We then fit Gaussian Mixture Models with two components using the normalmixEM function in R. A threshold was derived representing the mean of the calculated mu of both components, resulting in a threshold 0.08 BPND. This threshold separated the two clusters with minimal overlap. We used the average medial temporal atrophy rating (MTA) on MRI as biomarker for N as determined by experienced neuroradiologists. Raters were blinded to amyloid status. For individuals < 65 years of age, an average MTA score of ≥ 1 was considered positive; for individuals ≥ 65 years of age, an average MTA score ≥ 1.5 was considered positive [22]. Additionally, white matter hyperintensities were visually assessed using the Fazekas scale (range 0–3) [23]. Microbleeds were assessed on T2-weighted images and defined as small dot-like hypointense lesions. They were counted and dichotomized into absent (0) or present (≥ 1 microbleed).

Neuropsychological tests

All participants underwent annual standardized neuropsychological assessments [13]. For the memory domain, we used the Visual Association Test version A (VAT-A) and the total immediate and delayed recall condition of the Dutch version of the Rey auditory verbal learning task (RAVLT). For the language domain, we used category fluency (animals). For the attention domain, we used the Trail Making Test A (TMT-A) and Stroop task I and II (naming and color naming). For the domain of executive functioning, we used the TMT-B and Stroop task III (color-word). For global cognition, we used the Mini Mental State Examination (MMSE). Because the data were right-skewed, the raw test scores for TMT and Stroop were log transformed. Subsequently, values were inverted, so that a lower score implies worse test performance for all tests. We used available test results of visits before as well as after PET scans, in order to accurately estimate the cognitive slope. The neuropsychological tests administered most closely to baseline [18F]florbetapir were defined as baseline test results. In total, we used longitudinal cognitive data covering 4.9 ± 2.8 years. The proportion of missing tests ranged from 2.7% for MMSE to 8.5% for Stroop II and III. In total, 447 neuropsychological investigations of 92 patients were available (92 ≥ 2 visits, median 4).


All analyses are conducted in R version 4.0.3. We first compared demographic and clinical variables between baseline A− and A+ individuals using t-test, chi-square, or Mann-Whitney U test where appropriate.

Next, we described changes in biomarker status over time. We first investigated changes in A, T, and N biomarkers separately and then combined in ATN profiles. Then, we examined changes in amyloid status more closely. We categorized (change in) amyloid status as a four-level variable: negative at baseline and follow-up (negative-negative), negative at baseline and positive at follow-up (negative-positive), positive at baseline and negative at follow-up (positive-negative), and positive at baseline and follow-up (positive-positive). We investigated change in amyloid status in relation to actual BPND values at baseline and follow-up, using a division into low, grey zone, and high BPND with previously described thresholds by our group of 0.19 and 0.29 BPND [6]. Next, we investigated which factors were associated with change from a negative to a positive amyloid status using logistic regression analyses. In model 1, baseline age, sex, education, baseline MMSE score, and APOE ε4 carriership were evaluated as individual predictors, with the group remaining A− at follow-up as reference group. In model 2, all predictors were entered simultaneously. In an additional analysis, we used amyloid accumulation rate as outcome, using linear mixed models (outcome: BPND composite ROI). We again assessed baseline age, sex, education, baseline MMSE score, and APOE ε4 carriership as predictors. In model 1, variables were assessed individually, and each analysis included the variable of interest, time, and the interaction between the variable and time. Model 2 included all predictors simultaneously (including time and all interactions between predictors and time).

Last, we used change in amyloid status as predictor of cognitive test performance over time, using linear mixed models. We used our four-level variable reflecting change in amyloid status, time, and their interaction as predictors (negative-negative (reference), negative-positive, positive-negative, and positive-positive). Baseline age, sex, and education were used as covariates. Outcome were neuropsychological test scores. Models included a random intercept and additionally a random slope when it improved the model (random slope included for VAT-A, TMT-A, Stroop I-III and MMSE). Separate analyses were run with different tests as outcome.



Ninety-two individuals were on average 65 ± 8 years old, 39 (42%) were female and 27 (31%) APOE ε4 carrier (Table 1). At baseline, 24 (26%) individuals were A+. By design, A+ individuals had higher baseline amyloid burden. Additionally, they were more often APOE ε4 carrier and had higher baseline tau burden than those who were A−. MTA score, Fazekas score, number of microbleeds, and baseline neuropsychological test scores did not differ between A− and A+ individuals. There were no significant differences in baseline demographics between individuals with complete ATN biomarker information at follow-up and those who did not have complete ATN biomarker information at follow-up available.

Table 1 Baseline demographics

ATN biomarkers over time

We first examined changes in A, T, and N biomarkers individually. Figure 1 shows changes in biomarker status over time. Several individuals changed from negative to positive status (A: n = 10 (11%); T: n = 6 (14%); N: n = 7 (9%)). For A and N but not for T, a smaller number of individuals changed from a positive to a negative status (A: n = 5 (5%); N: n = 4 (5%)).

Fig. 1
figure 1

Changes in biomarker status for A, T, and N biomarker groups. Visualization of longitudinal changes in biomarker status for A, T, and N biomarker groups

For individuals with complete biomarker information for A, T, and N at two time points (n = 39), Fig. 2 visualizes the trajectory of ATN profiles from baseline to follow-up. During follow-up, 17 (44%) changed to another ATN profile. The percentage of individuals with normal AD biomarkers changed from 62% at baseline to 46% at follow-up. Five percent of individuals fell within the category of non-AD pathologic change at baseline, which changed to 18% at follow-up. The percentage of individuals with biomarkers in the Alzheimer’s continuum changed from 33% at baseline to 36% at follow-up.

Fig. 2
figure 2

Changes in ATN profiles. Sankey diagram showing changes in distribution of ATN profiles at baseline and follow-up. REM, rapid eye movement; MCI, mild cognitive impairment; AD, Alzheimer’s disease

According to the most common model of the pathophysiology of AD, the expected sequence of biomarkers becoming abnormal would be A → T → N. Only six of the 17 individuals changing profile fit into this hypothetical sequence. The other eight changed to T+ or N+ while still being A−, or changed to N+ before T+. Finally, three participants changed to a better ATN profile (A−T−N+ → A−T−N− n = 1, A+T−N− → A−T−N− n = 2).

During the period of follow-up, three individuals showed clinical progression; to dementia with Lewy bodies (DLB) n = 1, MCI due to AD n = 1, and AD dementia n = 1. The individual who progressed to DLB changed from A−T−N− to A+T−N−.The individual who progressed to MCI due to AD had the A+T−N− profile at baseline and at follow-up. The individual who progressed to AD dementia changed from baseline A+T+N− to A+T+N+. The last two individuals both carried an APOE ε4 allele.

Change in amyloid status over time

To evaluate amyloid accumulation over time, Fig. 3 visualizes changes in amyloid status in relation to actual BPND values at baseline and follow-up, using a division into low, grey zone, and high BPND. Overall, BPND in the composite ROI increased with 0.011 (SE 0.002) annually (p-value 0.00). Most individuals who were negative at baseline and at follow-up on visual rating (i.e., negative-negative) had low baseline and low follow-up BPND (54/58), and most positive-positive individuals had high baseline and high follow-up BPND (14/19). The amyloid status of 15 individuals changed over time (positive-negative n = 5, negative-positive n = 10). Most positive-negative individuals had both low baseline and low follow-up BPND (4/5). The group of negative-positive individuals was quite heterogeneous in terms of BPND values and had at baseline and follow-up low (4/10), grey zone (1/10), or high (1/10) BPND. Two changed from low baseline BPND to grey zone BPND at follow-up, and two changed from grey zone BPND at baseline to high BPND at follow-up. When conversely focusing on the six individuals with grey zone BPND at baseline, three belonged to the negative-positive group, two to the positive-positive group, and one to the negative-negative group. This shows a considerable part of this group is on the verge of transitioning to a visually positive amyloid status.

Fig. 3
figure 3

Changes in amyloid status. Scatterplot showing baseline and follow-up BPND values. Different colors represent individuals with a negative amyloid PET scan at baseline and follow-up (negative-negative), a positive scan at baseline and a negative scan at follow-up (positive-negative), a negative scan at baseline and a positive scan at follow-up (negative-positive), and a positive scan at baseline and follow-up (positive-positive), respectively. The dashed lines represent a division in low, grey zone, and high amyloid burden and is based on a previous study by our group [6], with thresholds of 0.19 and 0.29 BPND. BPND, binding potential

Subsequently, we investigated which factors predicted a change in amyloid status from negative to positive. Logistic regression analysis showed that APOE ε4 carriers had higher odds of transitioning to a positive amyloid status (OR 5.22 (95% CI 1.23–22.75), Table 2). Baseline age, sex, education, and baseline MMSE score were not associated with a higher odds of changing to amyloid positivity. When we analyzed amyloid accumulation rate as continuous outcome using linear mixed models (BPND; Table 3, Fig. 4), we confirmed that APOE ε4 carriers had both higher baseline BPND values and a higher accumulation rate.

Table 2 Change from negative to positive amyloid status
Table 3 Associations with baseline amyloid burden and amyloid accumulation rate
Fig. 4
figure 4

Longitudinal trajectory of amyloid burden. Longitudinal trajectory of [18F]florbetapir BPND over time. Separate lines represent the trajectories for different values of age (A), sex (B), education (C), baseline MMSE (D), and APOE ε4 carriership (E) respectively

Associations between changes in amyloid status and cognitive test performance

Finally, we investigated whether change in amyloid burden was associated with cognitive test performance over time, using our four-level variable (negative-negative (reference), positive-negative, negative-positive, positive-positive) as determinant. We did not find associations between change in amyloid status and baseline cognitive test performance (Table 4). By contrast, we found several associations with cognitive slope, as individuals in the negative-positive group had a steeper slope than negative-negative individuals on Stroop I and III. Positive-positive individuals showed a steeper decline on RAVLT immediate and delayed recall, TMT-B, and Stroop III. Positive-negative individuals did not differ from negative-negative individuals with regards to their cognitive test performance.

Table 4 Associations between change in amyloid burden and cognitive test performance


In our sample of cognitively normal individuals with SCD, we found that biomarker abnormality increased over a 2.5-year period. There was considerable variability in the order of biomarkers becoming abnormal in the ATN classification, suggesting no fixed order. Change from A− to A+ was associated with steeper decline in tests of attention and executive function.

We showed that the number of individuals with an abnormal biomarker status increased for both A, T, and N, over a time course of 2.5 years. Most of these individuals changed from a negative to positive biomarker status, yet of note, a smaller number of individuals changed from positive to negative. There are not many longitudinal studies investigating changes in the ATN classification; hence, the phenomenon of change from a positive to a negative status has not yet received much attention. One study investigating amyloid burden excluded individuals who were amyloid positive at one time point, and negative at the next, but did not specify the number of individuals [9]. Another excluded the 5% of individuals with borderline amyloid PET burden, reducing the risk of individuals crossing the threshold due to small changes [5]. Other studies investigating amyloid accumulation rate as continuous measure showed a negative slope in some individuals but did not address the possibility of reverting amyloid status and explained the negative slope by random variation, noise, or actual clearance of amyloid [7, 8]. One potential explanation for the five individuals changing from a positive to negative amyloid status by visual rating (positive-negative) could be that these scans were false-positive at baseline. While the quantitative measures might not have changed much over time, scan could be visually assessed differently at the two time points due to an imperfect intra-rater agreement [24,25,26]. This is part of clinical practice, especially in early disease stages. Therefore, acquiring follow-up scans is highly useful in individuals with equivocal scans with grey zone amyloid burden. Of note, one could also argue that also the negative-positive scans could be the result of rater variability and that their changing from negative to positive does not necessarily reflect clinical relevance. However, a substantial portion of these individuals had grey zone amyloid burden at baseline, which is already associated with a changed slope in memory function, as shown by our group previously [6]. We found that this group has a steeper decline in performance on Stroop I and III, which are indicative of attention and executive functioning. This is in line with other studies showing that amyloid burden in the subthreshold range is associated with cognitive decline and highlights the clinical relevance of grey zone amyloid burden [7, 8]. In general, an amyloid status based on visual assessment is not identical to an amyloid status based on a threshold for quantitative measures. Quantitative measures are not directly affected by rater variability and could therefore be interpreted as more consistent. However, quantitative measures of amyloid burden are often averaged over a larger ROI. If a scan is visually assessed as A+ based on a relatively small area, this does not necessarily translate in a higher average BPND in the total ROI, which could be a potential cause of differences between the two approaches. Overall, we found a relatively high degree of changing biomarkers in a short time frame. These results add to the literature suggesting the clinical relevance of changing from a negative to a positive amyloid status.

When we compared ATN profiles over time, we found 44% of individuals changed to a different ATN profile during 2.5 years of follow-up. Data on changing biomarkers enable the evaluation of the actual sequence of biomarker abnormality. Of note, most (11/17) individuals followed a different sequence than the overall accepted hypothesis of A becoming abnormal first, then T and N last [2]. In our sample, individuals changed to T+ or N+ while still being A− or changed to N+ before T+. These findings are in line with those of a former study investigating change in ATN profiles, which also found multiple sequences [5]. There are several possible explanations for these observations. First, amyloid could already be accumulating in the subthreshold range in individuals changing to T+ or N+, but before A+, suggesting the pathological process has started just below the detection threshold. An alternative explanation is the suggestion of the dual-pathway hypothesis, in which amyloid and tau accumulation are both the result of a common upstream event, not necessarily causally related to each other [27]. Finally, there could be mixed pathology, resulting in N+ due to other diseases than AD, hence not related to a specific ordering of events. Overall, the number of individuals with the A−T−N− profile became smaller and the number of individuals with non-AD pathologic change (A−T+N−, A−T−N+, A−T+N+) became larger at follow-up. In a previous study by our group, but also in other studies, these profiles did not have a higher risk of cognitive decline or clinical progression to MCI or dementia [3, 28].

When we evaluated determinants of change to amyloid positivity, we found APOE ε4 carriers had a higher baseline amyloid burden, a higher risk of transition from A− to A+ and a higher annual amyloid accumulation rate. Several studies confirm a relationship between ε4 carriership and a higher accumulation rate [29,30,31], although not all [7, 32]. The relationship between ε4 carriership and a higher risk of change from A− to A+ has also been confirmed [9, 33]. We add to these results with the finding that ε4 carriership is also associated with risk of change in a sample of cognitively normal individuals with SCD. We did not find evidence for an association with any of the other factors examined, such as baseline age, sex, or education level. In apparent contrast with former studies [9, 30], we did not find a relationship between a lower baseline cognitive performance and subsequent amyloid accumulation. Reasons for this inconsistency could be that an inclusion criterion for our study is normal performance at baseline and that variability in baseline cognition is small. Therefore, relationships with amyloid accumulation may be obscured. In short, our results suggest A− individuals who are ε4 carrier are still at risk of progression to A+.

Limitations of our study include that our sample size was relatively small. With a larger sample size, our study would have had more power to detect more subtle determinants of changes in A status. The results of our analyses examining changing amyloid status as predictor of cognitive decline should also be interpreted with caution and replicated in larger samples. Furthermore, we used [18F]flortaucipir PET as measure of tau burden. We pragmatically used Gaussian mixture modeling of [18F]flortaucipir to obtain a threshold, although there might be other approaches. Nevertheless, our approach resulted in a percentage of T+ which lies within the range of T+ described in other studies in cognitively normal individuals [3, 34,35,36]. Of note, during the recruitment of individuals for the [18F]flortaucipir PET scan, we slightly oversampled A+ individuals. Because substantial tau pathology within A− cognitively normal individuals is not expected to be present, we selected more A+ individuals for the [18F]flortaucipir PET in order to have a broader spectrum of amyloid and tau pathology. Therefore, our results might not reflect the true prevalence of amyloid and tau pathology in cognitively normal individuals and the results might not be directly generalizable to the general population. Another factor that potentially impacts generalizability is the fact that the individuals in our sample were mainly recruited at a memory clinic. Strengths include the longitudinal nature of the study with the availability of biomarkers, diagnoses, and cognition with substantial duration of follow-up. Furthermore, we used dynamic scan protocols which enabled us to calculate BPND, which is a more accurate measure of amyloid and tau load than the semi-quantitative SUVr. Another strength is our use of [18F]flortaucipir for the definition of “T,” since it does not suffer from off-target binding to amyloid plaques or TDP-43 and correlates well with Braak neurofibrillary tangle stages [37].

Concluding, we showed biomarker status changes in cognitively normal individuals with SCD. There was considerable variability in the sequence of ATN biomarkers becoming abnormal, suggesting that there is not one (causal) order of events. Changing from a negative to positive amyloid status was associated with APOE ε4 carriership and predicted subtle cognitive decline, suggesting the potential clinical relevance of amyloid burden in the negative range.

Availability of data and materials

The datasets supporting the conclusions of this article are available upon reasonable request.


  1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):263–9.

    Article  Google Scholar 

  2. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.

    Article  Google Scholar 

  3. Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, et al. ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project. Neurology. 2020;95(1):e46–58.

    Article  CAS  Google Scholar 

  4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science (New York, NY). 2002;297(5580):353–6.

    Article  CAS  Google Scholar 

  5. Tan MS, Ji X, Li JQ, Xu W, Wang HF, Tan CC, et al. Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia. Alzheimers Res Ther. 2020;12(1):55.

    Article  CAS  Google Scholar 

  6. Ebenau JL, Verfaillie SCJ, van den Bosch KA, Timmers T, Wesselman LMP, van Leeuwenstijn M, et al. Grey zone amyloid burden affects memory function: the SCIENCe project. Eur J Nucl Med Mol Imaging. 2021;48(3):747–56.

    Article  CAS  Google Scholar 

  7. Landau SM, Horng A, Jagust WJ. Memory decline accompanies subthreshold amyloid accumulation. Neurology. 2018;90(17):e1452–e60.

    Article  CAS  Google Scholar 

  8. Farrell ME, Chen X, Rundle MM, Chan MY, Wig GS, Park DC. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology. 2018;91(19):e1809–e21.

    Article  CAS  Google Scholar 

  9. Elman JA, Panizzon MS, Gustavson DE, Franz CE, Sanderson-Cimino ME, Lyons MJ, et al. Amyloid-β positivity predicts cognitive decline but cognition predicts progression to amyloid-β positivity. Biol Psychiatry. 2020;87(9):819–28.

    Article  CAS  Google Scholar 

  10. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7(3):270–9.

    Article  Google Scholar 

  11. Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, et al. Quantification of [(18)F]florbetapir: a test-retest tracer kinetic modelling study. J Cerebr Blood Flow Metab. 2019;39(11):2172–80.

    Article  Google Scholar 

  12. Golla SSV, Timmers T, Ossenkoppele R, Groot C, Verfaillie S, Scheltens P, et al. Quantification of tau load using [(18)F]AV1451 PET. Mol Imaging Biol. 2017;19(6):963–71.

    Article  CAS  Google Scholar 

  13. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam dementia cohort. J Alzheimer’s Dis. 2014;41(1):313–27.

    Article  Google Scholar 

  14. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19(4):224–47.

    Article  Google Scholar 

  15. Lammertsma AA. Forward to the past: the case for quantitative PET imaging. J Nuclear Med. 2017;58(7):1019–24.

    Article  CAS  Google Scholar 

  16. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage. 1997;6(4):279–87.

    Article  CAS  Google Scholar 

  17. Verfaillie SC, Golla SSV, Timmers T, Tuncel H, van der Weijden CWJ, Schober P, et al. Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer's disease and healthy controls: A test-retest study. J Cereb Blood Flow Metab. 2021;41(3):569–78.

  18. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer’s disease and cognitively normal subjects. J Nuclear Med. 2012;53(3):378–84.

    Article  CAS  Google Scholar 

  19. Bucci M, Savitcheva I, Farrar G, Salvadó G, Collij L, Doré V, et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [(18)F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging. 2021;48(7):2183–99.

    Article  CAS  Google Scholar 

  20. Shimokawa N, Akamatsu G, Kadosaki M, Sasaki M. Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation. Ann Nucl Med. 2020;34(9):629–35.

    Article  CAS  Google Scholar 

  21. Berron D, Vogel JW, Insel PS, Pereira JB, Xie L, Wisse LEM, et al. Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain J Neurol. 2021;144(9):2771–83.

    Article  Google Scholar 

  22. Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens P, Muller M, et al. MRI visual ratings of brain atrophy and white matter hyperintensities across the spectrum of cognitive decline are differently affected by age and diagnosis. Front Aging Neurosci. 2017;9:117.

    Article  Google Scholar 

  23. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351–6.

    Article  CAS  Google Scholar 

  24. Oh M, Seo M, Oh SY, Kim H, Choi BW, Oh JS, et al. Clinical significance of visually equivocal amyloid PET findings from the Alzheimer’s Disease Neuroimaging Initiative cohort. Neuroreport. 2018;29(7):553–8.

    Article  Google Scholar 

  25. Okada Y, Kato T, Iwata K, Kimura Y, Nakamura A, Hattori H, et al. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study. Ann Nucl Med. 2020;34(2):108–18.

    Article  CAS  Google Scholar 

  26. Bischof GN, Bartenstein P, Barthel H, van Berckel B, Doré V, van Eimeren T, et al. Toward a universal readout for (18)F-labeled amyloid tracers: the CAPTAINs study. J Nucl Med. 2021;62(7):999–1005.

    Article  CAS  Google Scholar 

  27. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron. 2008;60(4):534–42.

    Article  CAS  Google Scholar 

  28. Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol. 2016;15(10):1044–53.

    Article  Google Scholar 

  29. Guo T, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM. Alzheimer’s disease neuroimaging I. association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology. 2020;95(15):e2075–e85.

    Article  CAS  Google Scholar 

  30. Koychev I, Vaci N, Bilgel M, An Y, Muniz GT, Wong DF, et al. Prediction of rapid amyloid and phosphorylated-tau accumulation in cognitively healthy individuals. Alzheimer’s Dement (Amsterdam, Netherlands). 2020;12(1):e12019.

    Google Scholar 

  31. Toledo JB, Habes M, Sotiras A, Bjerke M, Fan Y, Weiner MW, et al. APOE effect on amyloid-β PET spatial distribution, deposition rate, and cut-points. J Alzheimer’s Dis. 2019;69(3):783–93.

    Article  CAS  Google Scholar 

  32. Whitwell JL, Tosakulwong N, Weigand SD, Graff-Radford J, Duffy JR, Clark HM, et al. Longitudinal amyloid-β PET in atypical Alzheimer’s disease and frontotemporal lobar degeneration. J Alzheimer’s Dis. 2020;74(1):377–89.

    Article  CAS  Google Scholar 

  33. Hatashita S, Wakebe D, Kikuchi Y, Ichijo A. Longitudinal assessment of amyloid-β deposition by [18F]-flutemetamol PET imaging compared with [11C]-PIB across the spectrum of Alzheimer’s disease. Front Aging Neurosci. 2019;11:251.

    Article  CAS  Google Scholar 

  34. Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, et al. Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16(6):435–44.

    Article  CAS  Google Scholar 

  35. Ingala S, De Boer C, Masselink LA, Vergari I, Lorenzini L, Blennow K, et al. Application of the ATN classification scheme in a population without dementia: findings from the EPAD cohort. Alzheimer’s Dement. 2021;17(7):1189–204.

    Article  CAS  Google Scholar 

  36. Eckerström C, Svensson J, Kettunen P, Jonsson M, Eckerström M. Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. Alzheimer’s Dement (Amsterdam, Netherlands). 2021;13(1):e12031-e.

    Google Scholar 

  37. Marquié M, Verwer EE, Meltzer AC, Kim SJW, Agüero C, Gonzalez J, et al. Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case. Acta neuropathologica communications. 2017;5(1):75.

    Article  CAS  Google Scholar 

Download references


Not applicable.


Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The SCIENCe project is supported by research grants from Gieskes-Strijbis fonds and stichting Dioraphte. [18F]florbetapir and [18F]flortaucipir PET scans were funded by AVID. WF and PS are recipients of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). Wiesje van der Flier holds the Pasman chair. Frederik Barkhof is supported by the NIHR biomedical research center at UCLH. Part of participant recruitment was accomplished through the Dutch Brain Research Registry, an online registry that facilitates participant recruitment for neuroscience studies ( in the Netherlands and is funded by ZonMw-Memorabel (project no 73305095003), Amsterdam Neuroscience, Alzheimer Nederland, and Brain Foundation Netherlands. FB is supported by the NIHR biomedical research center at UCLH.

Author information

Authors and Affiliations



JE, BB, and WF contributed to study concept and design. JE, DV, LK, ML, AH, AW, SG, RB, PS, FB, BB, and WF contributed to data acquisition. JE analyzed the data. JE and WF contributed to drafting of text and figures. All authors approved and critically evaluated the manuscript.

Corresponding author

Correspondence to Jarith L. Ebenau.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the medical ethical committee of the VU University and was in accordance with the Helsinki Declaration of 1975. All participants gave written informed consent.

Consent for publication

Not applicable.

Competing interests

Jarith Ebenau reports no disclosures relevant to the manuscript.

Denise Visser reports no disclosures relevant to the manuscript.

Lior Kroeze reports no disclosures relevant to the manuscript.

Mardou van Leeuwenstijn reports no disclosures relevant to the manuscript.

Argonde van Harten reports no disclosures relevant to the manuscript.

Albert Windhorst reports no disclosures relevant to the manuscript.

Sandeep Golla reports no disclosures relevant to the manuscript.

Ronald Boellaard reports no disclosures relevant to the manuscript.

Philip Scheltens has acquired grant support (for the institution) from Biogen. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Probiodrug Biogen, EIP Pharma, Merck AG.

Frederik Barkhof is a consultant for Biogen-Idec, Bayer-Schering, Merck-Serono, Roche, NovartisIXICO and Combinostics; has received sponsoring from European Commission-Horizon 2020, National Institute for Health Research-University College London Hospitals Biomedical Research Centre, TEVA, Novartis, and Biogen; and serves on the editorial boards of Radiology, Brain, Neuroradiology, Multiple Sclerosis Journal, and Neurology.

Bart van Berckel has received research support from EU-FP7, CTMM, ZonMw, NWO, and Alzheimer Nederland. BvB has performed contract research for Rodin, IONIS, AVID, Eli Lilly, UCB, DIAN-TUI, and Janssen. BvB was a speaker at a symposium organized by Springer Healthcare. BvB has a consultancy agreement with IXICO for the reading of PET scans. BvB is a trainer for GE. BvB only receives financial compensation from Amsterdam UMC.

Wiesje van der Flier Research programs have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, Biogen MA Inc., Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF has performed contract research for Biogen MA Inc and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc., Danone, Eisai and WebMD Neurology (Medscape). WF is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF was associate editor at Alzheimer’s Research & Therapy (2020-2021); she is associate editor of Brain (2021-). All funding is paid to her institution.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ebenau, J.L., Visser, D., Kroeze, L.A. et al. Longitudinal change in ATN biomarkers in cognitively normal individuals. Alz Res Therapy 14, 124 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: